Novartis Japanese Unit Moves Drug For Treating Several Cancers
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharma KK of Japan says it plans to seek approval for a pancreatic-cancer drug as early as next year, after it completes current Phase III trials. The Japanese arm is developing the drug through several stages for various treatments, leading with an application already filed for using it to treat renal cell carcinoma. Novartis Pharma also expects to begin Phase III trials for RAD001 within a year for treating stomach cancer. (Click here for more - a subscription may be required